PACTG P1061S: IMMUNOLOGIC MEMORY AFTER VACCINATION IN HAART-TREATED CHILDREN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是确定感染艾滋病毒的儿童在接种肺炎球菌、乙肝病毒和麻疹疫苗3-4年后是否有免疫应答的证据。在之前的一项研究中--P1024(SPID#1071)--HIV感染儿童接种了肺炎球菌疫苗、乙肝疫苗和MMR疫苗，并在18个月时出现应答，滴度下降。 在这项后续研究中，将研究大约149名受试者，最多224名受试者。研究人群将包括6至23岁(筛查/入选)的艾滋病毒感染者，他们在接受HAART治疗的同时于6/1/01至3/31/02登记参加P1024，并完成了最初的两年P1024研究期。这项研究将评估在第一次研究中失去免疫力的儿童，以及那些在加强接种后从阴性抗体转为阳性抗体的儿童。这些发现将与HIV RNA和CD4水平相关。这项研究具有非常重要的临床意义。感染艾滋病毒的儿童罹患这些疾病并发症的风险更高，有必要了解疫苗的持久性以及是否需要加强疫苗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of this study is to determine whether HIV-infected children have evidence of an immunization response to pneumococcal, hepatitis B virus (HBV) and measles vaccine 3-4 years after vaccination. In a previous study - P1024 (SPID #1071) - HIV-infected children received pneumococcal, HBV and MMR vaccines and experienced a response at 18 months, with declining titers. In this follow-up study approximately 149 subjects, up to a maximum of 224 subjects, will be studied. The study population will consist of HIV-infected subjects ages 6 to 23 years old (at screen/entry) who enrolled into P1024 between 6/1/01 and 3/31/02 while receiving HAART and completed the initial two-year P1024 study period. The study will evaluate children who lost immunity from the first study and those who convert from negative antibody to positive antibody after a booster vaccination. These findings will be correlated with HIV RNA and CD4 levels. This study is of highly significant clinical importance. Children with HIV are at higher risk to develop complications from these diseases and there is a need to know the durability of the vaccines and if boosters are needed.